251 related articles for article (PubMed ID: 16690963)
41. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
[TBL] [Abstract][Full Text] [Related]
42. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.
Solomon DA; Wang Y; Fox SR; Lambeck TC; Giesting S; Lan Z; Senderowicz AM; Conti CJ; Knudsen ES
J Biol Chem; 2003 Aug; 278(32):30339-47. PubMed ID: 12746453
[TBL] [Abstract][Full Text] [Related]
43. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract][Full Text] [Related]
44. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
45. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry.
Hui P; Howe JG; Crouch J; Nimmakayalu M; Qumsiyeh MB; Tallini G; Flynn SD; Smith BR
Leuk Lymphoma; 2003 Aug; 44(8):1385-94. PubMed ID: 12952233
[TBL] [Abstract][Full Text] [Related]
46. Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines.
Kitahara K; Yasui W; Yokozaki H; Semba S; Hamamoto T; Hisatsugu T; Tahara E
J Exp Ther Oncol; 1996 Jan; 1(1):7-12. PubMed ID: 9414383
[TBL] [Abstract][Full Text] [Related]
47. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
48. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas.
Medeiros LJ; Hai S; Thomazy VA; Estalilla OC; Romaguera J; Luthra R
Mod Pathol; 2002 May; 15(5):556-64. PubMed ID: 12011261
[TBL] [Abstract][Full Text] [Related]
49. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
50. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
51. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
52. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
53. CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA.
Thoms HC; Dunlop MG; Stark LA
Cell Cycle; 2007 Jun; 6(11):1293-7. PubMed ID: 17525529
[TBL] [Abstract][Full Text] [Related]
54. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
Shishodia S; Amin HM; Lai R; Aggarwal BB
Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
[TBL] [Abstract][Full Text] [Related]
55. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
[TBL] [Abstract][Full Text] [Related]
56. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Lo RK; Kwong YL
Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
[TBL] [Abstract][Full Text] [Related]
57. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Saab R; Bills JL; Miceli AP; Anderson CM; Khoury JD; Fry DW; Navid F; Houghton PJ; Skapek SX
Mol Cancer Ther; 2006 May; 5(5):1299-308. PubMed ID: 16731763
[TBL] [Abstract][Full Text] [Related]
58. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
59. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma.
Gladden AB; Woolery R; Aggarwal P; Wasik MA; Diehl JA
Oncogene; 2006 Feb; 25(7):998-1007. PubMed ID: 16247460
[TBL] [Abstract][Full Text] [Related]
60. [Detection of cyclin D1 mRNA by reverse transcription-polymerase chain reaction in paraffin-embedded tissues and its diagnostic significance for mantle cell lymphoma].
Shui RH; Wei YK; Sun MH; Wang J; Shi DR; Zhang TM; Jin AP; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 Aug; 34(8):514-8. PubMed ID: 16383299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]